Part of the problem is, as obesity theorist and computational physiologist Edward Archer bluntly says, much of the “[nutrition] data is meaningless.” One of the things that the FDA should remember is ...

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

Researchers identify a significant association between sugar-sweetened beverage tax and BMI changes among adults living in ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

In the US, 1 in 7 adults are experiencing some type of chronic kidney disease caused by diabetes. The new approval therefore allows doctor to prescribe Ozempic to lower the risk of kidney failure, ...

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

In a Senate hearing, Robert F. Kennedy, Jr. said that efforts to address the high rates of chronic disease need to start with ...